Hungarian patients to benefit from subsidy for 31 innovative drugs

Thousands of Hungarian patients may have better life prospects after a decision was made again to include new therapies to the social security subsidy system following a two-year pause. As a result, 31 new medicines or indications will now be available under regular subsidy thanks to a regulation published at the end of December.

Through the medicinal products newly included in the subsidy system, thousands of patients with diseases including various cancers, hemophilia, heart failure, Parkinson’s disease, multiple sclerosis, inflammatory arthritis or asthma may receive state-of-the-art treatments. With the current decision, Hungary is getting closer to catching up on the enforced and significant backlog caused by the pandemic in terms of the inclusion of new therapies in the social security subsidy system. There is every chance for this, as the National Health Insurance Fund of Hungary has submitted an additional 75 applications for decision.

“The continuous expansion of the range of subsidized products is essential in order for the most modern globally accessible therapies to become widely available also in Hungary for the effective and efficient treatment of more and more serious diseases,” said Dr Peter Holchacker director of the trade group Association of Innovative Pharmaceutical Manufacturers (AIPM).